icone plus
Contact
Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité DUPIXENT (dupilumab).
Voir aussi
Décision d'accès précoce
14/11/2024
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
jArdKfrGhgAvpBpL